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A B S T R A C T
The pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin were determined following oral
administration in 21 Asian house geckos (Hemidactylus frenatus) at a dose of 10 mg/kg. Changes in enrofloxacin
and ciprofloxacin plasma concentrations were quantified at regular intervals over 72 h (1, 2, 6, 12, 24, 48, and
72 h). Samples were analysed by high-pressure liquid chromatography (HPLC) and the enrofloxacin pharma-
cokinetic data underwent a two-compartment analysis. Due to the limited ciprofloxacin plasma concentrations
above the lower limit of quantification (LLOQ), the ciprofloxacin data underwent non-compartment analysis and
the half-life was determined by the Lineweaver-Burke plot and analysis. The enrofloxacin and ciprofloxacin
mean half-lives (t½) were 0.95 h (α) / 24.36 h (β), and 11.06 h respectively, area under the curve (AUC0-24h)
were 60.56 and 3.14 µg/mL*h, respectively, maximum concentrations (Cmax) were 12.31 and 0.24 µg/mL, re-
spectively, and time required to reach the Cmax (Tmax) were 1 and 2 h respectively. Enrofloxacin was minimally
converted to the active metabolite ciprofloxacin, with ciprofloxacin concentrations contributing only 4.91% of
the total fluoroquinolone concentrations (AUC0-24h). Based on the pharmacokinetic indices when using sus-
ceptibility breakpoints when determined at mammalian body temperature it is predicted that single oral ad-
ministration of enrofloxacin (10 mg/kg) would result in plasma concentrations effective against susceptible
bacterial species inhibited by an enrofloxacin MIC ≤ 0.5 µg/mL in vitro, but additional studies will be required
to determine its efficacy in vivo.
1. Introduction
Reptile populations are threatened by invasive species, habitat de-
struction, climate change, pollution and infectious diseases
(Gibbons et al., 2000; Böhm et al., 2013). It is estimated that 34% of
reptile species are threatened (IUCN, 2019). Threatened species occur
across all orders of reptilians, however, smaller species such as skinks
and geckos within squamata are overrepresented (IUCN, 2019). To
prevent extinction of threatened reptiles, conservation breeding pro-
grams have been implemented globally. Captive management of rep-
tiles is not, however, without risk. Reptiles are often difficult to main-
tain in captivity requiring species-specific enclosures, diets, lighting,
temperature gradients and humidity. Failure to maintain best practice
captive husbandry can lead to maladaptation and immunosuppression,
and increase disease susceptibility, emergence and transmission
(Jacobson, 1993).
Examples of conservation breeding programs threatened by disease
are those for the Christmas Island endemic Lister's geckos
(Lepidodactylus listeri) and blue-tailed skinks (Cryptoblepharus egeriae)
(Rose et al., 2017). These species are extinct in the wild on Christmas
Island, but are sustained in captive breeding programs. In 2014 an
outbreak of a biofilm-forming Enterococcus sp. (proposed Enterococcus
lacertideformus. nov.) caused disease in the captive blue-tailed skinks
and Lister's geckos (Rose et al., 2017), and likely occurred as a direct
spillover from invasive Asian house (Hemidactylus frenatus) and mute
(Gehyra mutilata) geckos. Microscopically, bacteria formed colonies
surrounded by a biofilm-like matrix replacing normal tissue. Infection
appeared to start in the head, as the disease progressed, it became
https://doi.org/10.1016/j.vas.2020.100116
Received 12 January 2020; Received in revised form 21 April 2020; Accepted 21 April 2020
⁎ Corresponding author at: The University of Sydney, J.L. Shute Building C01A, 425 Werombi Road, Camden, NSW 2570, Australia
E-mail address: jessica.agius@sydney.edu.au (J.E. Agius).
Veterinary and Animal Science 9 (2020) 100116
Available online 05 May 2020












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J.E. Agius, et al. Veterinary and Animal Science 9 (2020) 100116
2
systemic and the animal died. An unusual feature of this disease was the
minimal or complete absence of a host immune response. Although the
outbreak was effectively managed through quarantine, a significant
threat to the breeding stock remained (Rose et al., 2017). Treatment
was not considered because the organism had not been morphologically
or genetically characterised, and there was no data on the pharmaco-
kinetic profile of any antimicrobials in reptiles (less than 10 g in
bodyweight).
Enrofloxacin, a fluoroquinolone, is a bactericidal, broad-spectrum
antimicrobial that has therapeutic activity against both aerobic gram-
negative and gram-positive bacteria (Schroder, 1989). This anti-
microbial also inhibits biofilm formation in some bacteria (Yang et al.,
2017). Enrofloxacin is commonly used in reptile medicine because of its
favourable pharmacokinetic profile and therapeutic index
(Salvadori and Vito, 2015), and formation of its active metabolite ci-
profloxacin, contributes to the antimicrobial efficacy (Walker et al.,
2000).
A small number of pharmacokinetic studies have been undertaken
in reptiles (Table 1) and predominantly in crocodilians, chelonians, and
snakes. Only three studies have been published in lizards
(Hungerford et al., 1997; Maxwell and Jacobson, 2008; Salvadori et al.,
2017) and none in smaller species of skinks and geckos. Based on these
studies, significant variations in rates of enrofloxacin metabolism,
conversion of enrofloxacin to ciprofloxacin, and elimination of enro-
floxacin have been reported. As a result, it is difficult to accurately
predict the pharmacokinetic profiles of enrofloxacin in unstudied rep-
tiles. These limitations highlight the importance of conducting species-
specific pharmacokinetic and pharmacodynamic (PK/PD) studies to
identify effective dosing regimens.
The aims of this study were to determine the pharmacokinetic
profile of enrofloxacin and ciprofloxacin following oral administration
of enrofloxacin in Asian house geckos used as a surrogate for the cri-
tically endangered Lister's gecko and blue-tailed skink which are of
similar mass. These findings will inform evidenced-based therapeutic
protocols that will have important implications for health and welfare
of other species of small lizards.
2. Materials and methods
2.1. Animal ethics
The use of wild reptiles was approved by The University of Sydney
Animal Ethics Committee, protocol 2018/1380 on 16 July 2018.
2.2. Animals and housing
Twenty-four outwardly healthy adult geckos (10 females, 14 males),
ranging in weight from 3.0 to 4.5 g (mean 3.4 g) were used in this
study. Geckos were classified as healthy if they had a body condition
score of 3 or greater (range 1 to 5), as determined by the amount of
muscling on the tail and the dorsal pelvis, were active, and had no
physical deformities or lesions. The geckos were captured within 200 m
of the Christmas Island Immigration Detention Centre (-10.472023,
105.578303), where E. lactertideformusinfected geckos have not been
observed. The geckos were individually housed in PenPal terrariums
(30 cm x 18 cm x 18 cm) (Living World® PenPals) in a biosecure facility
and acclimatised for a minimum period of one week prior to study
commencement. Animals were kept at ambient temperatures (24 to
26°C), with relative humidity ranging between 80% and 85%, and were
exposed to a 12 h photoperiod. Animals were fed three days per week a
mixture of termites and crickets and fasted for three days prior to drug
administration and throughout the study period. Animals were mon-
itored daily during the acclimatisation and treatment period.
2.3. Experimental design
The geckos were randomly allocated into eight treatment groups
consisting of three animals. Each gecko (excluding baseline) was
weighed and then received a single-dose 10 mg/kg oral administration
of enrofloxacin (Enrotril® 25 mg/mL, Troy Laboratories Australia Pty
Ltd). A dose of 10 mg/kg was selected as it is the highest limit of the
suggested dose range of enrofloxacin for lizards (Allen et al., 1993;
Hungerford et al., 1997). Oral administration of enrofloxacin was per-
formed using a 29G insulin syringe with a blunt needle tip. The needle
was used to open the mouth and create a space between the lower and
upper rows of teeth to allow direct administration of enrofloxacin into
the back of the oral cavity. Any enrofloxacin not swallowed was re-
drawn and administered as above to minimise any loss of volume. A
treatment group was euthanised at time zero (baseline analysis), and at
1, 2, 6, 12, 24, 48 and 72 h after dosing. Prior to euthanasia, geckos
were given a subcutaneous injection of the sedative alfaxalone (Al-
faxan, Jurox Animal Health) (5 mg/kg). Once unresponsive, lizards
were decapitated and whole blood (40 to 80 µL) from the carotid artery
was collected into capillary tubes containing lithium heparin (Fisher
Scientific, Pennsylvania, USA). No coagulation of whole blood was
observed. Tubes were placed on ice. Within 10 min of collection plasma
was separated by centrifugation (2,000 x g) and frozen and protected
from light. Samples were stored at ˗20°C until transported to the Aus-
tralian mainland then stored at ˗80°C until analysis. Enrofloxacin
plasma concentration quantification occurred within four weeks of
blood collection. Plasma samples were heat sterilised at 60°C to satisfy
quarantine regulations (WHO, 2014). Known concentrations of enro-
floxacin and its active metabolite ciprofloxacin were added to un-
medicated plasma from the common brushtail possum(Trichosurus
vulpecula) (n = 1) and analysed before and after heat inactivation to
verify that enrofloxacin and ciprofloxacin concentrations were heat
stable.
2.4. Instrumentation and chromatographic conditions
Enrofloxacin and ciprofloxacin concentrations in plasma were
quantified by high-pressure liquid chromatography (HPLC) by the
Veterinary Pharmacology Unit, Sydney School of Veterinary Science,
The University of Sydney. The HPLC system consisted of Shimadzu LC-
20AT delivery unit, DGU-20A3 HT degassing solvent delivery unit, SIL-
20A auto injector unit, SIL-20A auto injector, RF-20A fluorescence
detector and CTO-20A column oven. Shimadzu LC solution software
(Kyoto, Japan) was used for chromatographic control, data collection
and processing.
Quantification of enrofloxacin and ciprofloxacin was modified from
previous validated protocols (Griffith et al., 2010; Black et al., 2014).
Optimal chromatographic separation was performed with a Synergy, 4
µm, Max-RP80A (150 × 4.6 mm) (Phenomenex, Lane Cove, NSW,
Australia) with a 1 mm optic-guard C-18 pre-column (Choice Analy-
tical, Thornleigh, NSW, Australia) at ambient temperature (26°C). The
isocratic mobile phase used consisted of a mixture of buffer containing
1% of tetrabutylammonium hydrogen sulfate, 5 mM sodium dodecyl
sulfate, and 0.2% triethylamine (Sigma-Aldrich, Castle Hill, NSW,
Australia), and HPLC grade acetonitrile (60:30, v/v) (Thermo Fisher
Scientific, Scoresby, VIC, Australia). The flow rate was 1 mL/min and
fluorescence detection occurred at an excitation wavelength of 280 nm
and an emission wavelength of 450 nm. Retention times of enro-
floxacin, ciprofloxacin and marbofloxacin as the internal standard (IS)
were 5.85, 5.44 and 3.85 min, respectively.
2.5. Sample processing
Stock solutions of the analytical standards enrofloxacin (purity ≥
98%), ciprofloxacin (purity ≥ 98%), and marbofloxacin (purity ≥
97%) (Sigma-Aldrich, Castle Hill, NSW, Australia) were prepared in
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acetonitrile at the concentration of 500 µg/mL. Nine standard con-
centrations of both enrofloxacin and ciprofloxacin, ranging from 0.039
to 10 µg/mL were prepared in water (purified deionised water [MilliQ]
in place of plasma as additional plasma for construction of the standard
curves was not available). Ten microlitres of tetrabutylammonium hy-
drogen sulfate (10%), and 20 µL of acetonitrile (containing 0.0625 µg/
mL IS) were added to 10 µL of the plasma samples (or 10 µL of water for
the standards), which were then vortexed and centrifuged at 14,000 x g
for 10 min. Twenty microlitres of the supernatant were transferred to
microcentrifuge tubes and 180 µL of the mobile phase was added. A
total volume of 5 µL per sample was injected into the chromatographic
system.
2.6. Standard curve validation
Due to the very low volume of gecko plasma available, in order to
confirm standard concentrations prepared in water were accurate, 1
µg/mL of enrofloxacin and ciprofloxacin were added into the gecko's
pooled plasma and were compared with the detected drugs’ con-
centration when 1 µg/mL of each drug were also added to water.
2.7. Quantification
Plasma concentrations of enrofloxacin and its active metabolite ci-
profloxacin, were simultaneously quantified. Both enrofloxacin and
ciprofloxacin were measured via standard curves (0.039 to 10 µg/mL)
where a weighting factor (1/ × 2) was used to establish regression of
the curve. The theoretical limit of the lower limit of detection (LLOD)
and lower limit of quantification (LLOQ) were estimated by 3.3 × y-
intercepts from the regression lines (σ) / mean slope of calibration
curves (S) and 3 × LLOD, respectively (ICH, 2015). Intra-assay preci-
sion and accuracy for high (10 µg/mL), middle (0.625 µg/mL), and low
(0.039 µg/mL) quality controls were calculated. Precision was calcu-
lated using the coefficient of variation [CV = (standard deviation /
mean value) × 100], and accuracy, expressed as bias was determined
by a percentage difference between estimated value and the nominal
value [Bias = (estimated value – nominal value) / nominal
value × 100].
2.8. Pharmacokinetic analysis
The mean and standard deviation drug concentration at each
timepoint consisted of the observed concentrations of three animals.
The enrofloxacin data were fitted to a non-compartment analysis, a one-
compartment model and a two-compartment model, the best fit was the
two-compartment model as the semi-log curve demonstrated two dis-
tinct slope gradients (Fig. 1 c) and had the lowest Akaike Information
Criterion (AIC) (Olofsen and Dahan, 2013). Calculations for the two-
compartment model can be found in (Riviere, 2011a) and were calcu-
lated by the PKSolver program (Zhang et al., 2010). The maximum
concentration (Cmax) of enrofloxacin in plasma, and the time required
to reach the Cmax (Tmax) were obtained directly from the measured
concentrations. The area under the enrofloxacin concentration-time
curve (AUC0–t) was also calculated manually by the log-linear trape-
zoidal method (Chiou, 1978). The ciprofloxacin semi-log curve ap-
peared linear over 24 hours (Fig. 1 d), however, the half-life was cal-
culated from the Lineweaver-Burke equation t1/2 = (0.693 x
(km + C))/Vmax (Riviere, 2011b). The AUC, area under the moment
curve (AUMC) and mean residence time (MRT) were also calculated for
ciprofloxacin over 24 hours.
The PK/PD index AUC/minimum inhibitory concentration (MIC)
was calculated by dividing the combined enrofloxacin and ciprofloxacin
AUC0-24h by the MIC of enrofloxacin to inhibit susceptible streptococci
isolates when grown at mammalian temperatures as documented as
susceptible breakpoints in CLSI document VET08 Table 2D
(CLSI, 2018). The data for Streptococci spp. were used as the MIC values
for enrofloxacin were not available for Enterococci spp. and the genus
Streptococcus is most closely related to the Enterococcus genus of bac-
teria. The ratio of enrofloxacin to ciprofloxacin for each timepoint up to
and including t = 24 h were calculated by dividing the average con-
centration of enrofloxacin by that of ciprofloxacin.
2.9. Plasma protein binding
A preliminary estimation of the plasma protein binding (PPB) of
enrofloxacin and ciprofloxacin in gecko plasma at concentrations of
0.72 and 0.35 µg/mL, respectively was determined in duplicate by the
modified ultrafiltration method (Dow, 2006). This involved 150 µL of
pooled gecko plasma treated with enrofloxacin and ciprofloxacin and
then incubated in a water bath at 26°C for 30 min. Ten μL of plasma was
removed for determination of the total enrofloxacin and ciprofloxacin
concentrations (Drugtotal), and the remaining plasma was transferred to
the reservoir of the Centrifree (Merk Millipore, Macquarie Park, Aus-
tralia) with a membrane molecular weight cut‐off of 30 kDa. The ul-
trafiltrate device was centrifuged at 1,500 x g for five mi at 26°C. After
centrifugation, the filtrate was used to determine the free enrofloxacin
and ciprofloxacin concentrations (Drugfree). Both the (Drugtotal) and
(Drugfree) fractions were analysed by HPLC as described previously. The
PPB of enrofloxacin and ciprofloxacin in gecko plasma was determined
by the following formula: PPB % = 100 − [(Drugfree/
Drugtotal) × 100]. In vitro testing was used to determine the degree of
non-specific binding to the ultrafiltrate device membrane, using phos-
phate buffer (pH 7.4) as a control.
3. Results
3.1. Experimental animals
All geckos remained healthy during the acclimatisation and study
periods.
3.2. Preliminary heat stability study
A negligible difference in the concentrations of enrofloxacin and
ciprofloxacin were detected between the heat-treated and non-heat-
treated plasma samples (± 0.1%) (Data not shown).
3.3. Accuracy and precision
For the standard curve validation in plasma, the accuracy and
precision of enrofloxacin and ciprofloxacin were < 15% and < 5%,
respectively. Recovery of enrofloxacin and ciprofloxacin from pooled
plasma samples were 94% and 102%, respectively, when compared to
the control prepared in water. There was a negligible difference of the
recovered drug and metabolite concentrations between plasma samples
and the control.
For the three standard concentrations of 0.039, 0.625 and 10 µg/mL
prepared in water, the average intra-assay accuracy for enrofloxacin
and ciprofloxacin varied between 85.03% and 110.89%, and 97.80%
and 110.09% respectively. The average intra-assay precision for enro-
floxacin and ciprofloxacin were 4.56%±0.00, 5.29%±0.03,
2.44%±0.26 and 4.58%±0.00, 3.95%±0.02, 1.70%±0.17 at
0.039, 0.625 and 10 µg/mL respectively. The LLOD and LLOQ were
0.84 ng/mL and 2.53 ng/mL, and 2.30 ng/mL and 6.91 ng/mL, for
enrofloxacin and ciprofloxacin, respectively.
3.4. Pharmacokinetic profile
The plasma concentrations of enrofloxacin and its active metabolite
ciprofloxacin are shown (Table 2), results presented as mean and
standard error (SE). The changes in enrofloxacin and ciprofloxacin
plasma concentrations vs time curves following oral administration are
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shown (Fig. 1). The pharmacokinetic indices for enrofloxacin and ci-
profloxacin are also shown (Table 3). Plasma concentrations of enro-
floxacin were above the LLOQ until 72 h. Plasma concentrations for
ciprofloxacin were detected at concentrations higher than the LLOQ for
all timepoints up to and including 24 h (Table 2). The Cmax of cipro-
floxacin (0.24 µg/mL) was 1.95% that of enrofloxacin (12.31 µg/mL).
Ciprofloxacin comprised 4.91% of the total fluoroquinolone AUC0-24h.
3.5. Plasma protein binding
The average PPB for enrofloxacin and ciprofloxacin in the geckos’
plasma were 51.33% and 27.92%, respectively. Non-specific binding of
enrofloxacin and ciprofloxacin to the microcentrifugation tube or filter
were 6.16% and 6.26%, respectively.
4. Discussion
The PK/PD indice such as AUC/MIC has been used to guide some
antimicrobial dosing regimens. Fluoroquinolones are considered con-
centration-dependant antibiotics (Turnidge, 1999), whereby such an-
tibiotics are considered efficacious based on the AUC to MIC ratio
(Toutain et al., 2017). Therefore, ideal dosing regimens maximise drug
concentrations to achieve effective antimicrobial therapy (Wright et al.,
2000). There are challenges associated with determining antibiotic
dosage rates in reptiles because published MIC susceptibility and re-
sistant breakpoints, as documented in CLSI VET08, are usually de-
termined for bacteria incubated at 35 to 37°C, the body temperature of
most mammals. No MIC studies have been published that inhibit En-
terococci spp. or well-studied and closely related Streptococci spp. grown
at the preferred optimum temperature zone of reptiles, however, MIC
antimicrobial susceptibility tests have been performed at 28, 22 and 18-
19°C in fish for other bacterial species (as reviewed in Smith et al.,
2002). Based on these studies, the MIC calculated at temperatures less
than mammalian body temperature can be lower, higher, or identical to
those calculated at mammalian body temperatures depending on the
antibiotic, but no studies on enrofloxacin's MIC to inhibit bacterial
species at less than mammalian body temperature have been reported.
Therefore, in this study, interpretations were limited to mammalian
susceptibility breakpoints for Streptococci spp. taken from CLSI docu-
ment VET08 Table 2D (CLSI, 2018).
The AUC/MIC ratio is the best PK/PD index of clinical outcome for
Fig. 1. Plasma concentrations of enrofloxacin and metabolite ciprofloxacin in Asian house geckos following oral administration of enrofloxacin at 10 mg/kg. (a)
Linear plot of mean enrofloxacin concentrations (± SE). (B) Linear plot of mean ciprofloxacin concentrations (± SE). (c) Semi-logarithmic plot of mean enrofloxacin
concentrations (± SE). (d) Semi-logarithmic plot of mean ciprofloxacin concentrations (± SE). Red data points, enrofloxacin; blue data points, ciprofloxacin; black
data points, observed concentrations for each gecko; broken line, lower limit of quantification (LLOQ).
Table 2
Plasma concentrations after oral administration of enrofloxacin (10 mg/kg) in
Asian house geckos, observations of three animals at each timepoint.
Enrofloxacin (µg/mL) Ciprofloxacin (µg/mL) E:C ratio
Time (h) Mean SE Mean SE Mean
1 12.31 7.95 0.17 0.04 72.13
2 10.90 6.53 0.24 0.03 45.29
6 2.20 0.29 0.19 0.05 11.72
12 1.10 0.03 0.13 0.02 8.43
24 0.66 0.16 0.06 0.02 11.77
48 0.31 0.10 0.02* 0.01 15.99
72 0.29 0.04 0.01* 0.01 25.01
SE, standard error of the mean.
⁎ plasma concentrations below the limit of quantification
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enrofloxacin to inhibit a bacterial pathogen in patients (Toutain et al.,
2017). Therefore, using a MIC of 0.5 µg/mL, the combined enrofloxacin
and ciprofloxacin AUC0-24h [63.70] / MIC [0.5] ratio is 127.40. It is
recommended that for the fluoroquinolones a minimum AUC/MIC ratio
of 120 to 125 are required for fluoroquinolones to achieve clinical
success in critically ill people (Levison and Levison, 2009). Conse-
quently, susceptible Streptococci spp. isolates would be considered sus-
ceptible to enrofloxacin (susceptible < 0.5 µg/mL, intermediate 1-2
µg/mL, resistant > 4 µg/mL) (CLSI, 2018).
In addition to the AUC/MIC ratio, multiple other host and pathogen
factors can impact the efficacy of enrofloxacin. For drugs that have a
high percentage of PPB, the AUC/MIC may be overestimated
(Levison and Levison, 2009). In reptiles, this is the first time enro-
floxacin and ciprofloxacin PPB has been estimated. Based on these
findings, enrofloxacin PPB estimate is similar to that in calves (46%)
(Davis et al., 2007) and therefore, PPB may have some impact on the
AUC/MIC ratio in this species. These findings must be considered pre-
liminary as due to the limited plasma, only one concentration of en-
rofloxacin (0.72 µg/mL) was undertaken when it is recommended that
drug PPB should be performed at low, medium and high drug con-
centrations (Dow, 2006). Additionally, for most accurate results it is
recommended that determination of PPB should be done with fresh
plasma (Riviere and Buur, 2011), however, only frozen plasma was
used here. Once the enrofloxacin and ciprofloxacin unbound fraction
have been confirmed in future studies, the fAUC/MIC would be a more
accurate indice than AUC/MIC (Toutain et al., 2017).
As this pathogen produces a thick biofilm (Rose et al., 2017) this
may also impact the efficacy of enrofloxacin to inhibit E. lacer-
tideformus. As an example, biofilm producing Staphylococcus aureus re-
quire an antimicrobial MIC up to 100 times higher than those that do
not produce biofilms (Girard et al., 2010; Di Domenico et al., 2018).
Additionally, factors associated with the infection site and host immune
status all affect the antibiotic's MIC to inhibit the pathogen
(Giguere and Dowling, 2013).
In many mammalian species enrofloxacin is bio-transformed to the
active metabolite ciprofloxacin via hepatic de-ethylation (Küng et al.,
1993). The rate of hepatic metabolism varies significantly in different
species including reptiles, and in some species conversion of enro-
floxacin to ciprofloxacin is limited (Fitzgerald and Vera, 2006;
Dimitrova et al., 2007; Ogino and Arai, 2007). Limited conversion rates
may be associated with poor expression of the enzyme responsible for
biotransformation (enzyme CYP450 3A) in some reptiles (Ertl et al.,
1998; Vaccaro et al., 2003), or their slow metabolism rates when kept at
temperatures below 37°C. In this study the mean plasma concentrations
of ciprofloxacin were minimally increased above the LLOQ, and fell
below it by 48 h, only contributing 4.91% of the total AUC0-24h for
enrofloxacin and ciprofloxacin. The low concentrations of ciprofloxacin
may be a function of a decreased metabolic rate associated with low
body temperature or be the result of a poorly developed metabolic
pathway for converting enrofloxacin to ciprofloxacin. Therefore, ci-
profloxacin may not contribute to the in-vivo efficacy of enrofloxacin at
25°C in geckos or does so minimally.
The validation of enrofloxacin and ciprofloxacin in water in place of
plasma was necessary due to the inability to obtain adequate volumes
of gecko plasma. The re-analysis of enrofloxacin using a single sample
of gecko plasma was undertaken and shown to be very similar in plasma
and water, however, future studies should use the target species’ plasma
for assay validation.
The time of maximum plasma concentration of enrofloxacin was at
the 1 h timepoint, however, the true Tmax may occur prior to, or after
this timepoint. Therefore, additional sampling timepoints between 0
and 2 hours would be necessary to adequately assess the true Cmax.
Though, the observed Tmax does indicate rapid oral absorption. In
contrast, delayed absorption was observed in red-eared sliders (5 h)
(James et al., 2003) and loggerhead sea turtles (20 h) (Jacobson et al.,
2005). Reasons for this marked variation are not known but may have
to do with the fact that the turtles were not fasted and the presence of
food in the stomach may have delayed absorption, or due to differences
in species’ metabolic rates.
Fig. 1 c demonstrates two distinct curve gradients for enrofloxacin
therefore, a two-compartment model was used to analyse this data. The
enrofloxacin half-life α is approximately 1 h, however the half-life β is
approximately 24 h suggesting that the drug has a longer duration in
peripheral compartments. Enrofloxacin half-life at the same adminis-
tration route and dosage used in this study was 32.84 hours in red-eared
sliders (James et al., 2003) and 37.8 hours in loggerhead sea turtles
(Jacobson et al., 2005).
When delivering a small volume of medication to a small animal
orally, it is difficult to ensure all medication is consumed. This may
explain the variability of plasma concentrations observed between re-
plicates at some timepoints. It is likely, however, with repeated dosing,
which would be required to achieve therapeutic drug concentrations,
the impact of variation in dosage due to the challenges of oral admin-
istration would be minimised. An alternate approach to oral delivery
would be administering the drug via a feeding tube into the oeso-
phagus. This method, however, would be stressful, require adjustments
to compensate for increased dead-space in the delivery system, and
cause abrasions to the oral mucosa, and so was not used in this study.
Parenteral injection of enrofloxacin would result in consistent drug
Table 3
Mean pharmacokinetic indices for enrofloxacin and the metabolite cipro-
floxacin in Asian house geckos after single-dose oral administration of 10 mg/
kg enrofloxacin. PK indices for enrofloxacin determined using a two-compart-
ment model; t1/2 of ciprofloxacin determined by the Lineweaver-Burke equa-
tion/plot (Riviere, 2011b). Blank cells denote not applicable.
Indices Units Enrofloxacin Ciprofloxacin
Cmax µg/mL 12.31 0.24





t1/2 α 1/h 0.95
t1/2 β 1/h 24.36
AUC0–24h µg/mL*h 60.56 (59.28) 3.14
AUMC0–24h µg/mL*h2 1303.87 30.13
MRT0–24h h 16.48 9.63








Cmax, maximum drug concentration; Tmax, time of maximum plasma con-
centration; t1/2,terminal half-life; k10, elimination rate constant from central
component; k12, inter-compartment rate constant from central to peripheral
compartment; k21, inter-compartment rate constant from peripheral to central
compartment; t1/2 α,distributive half-life; t1/2 β, elimination half-life; AUC0–24h,
area under the concentration-time curve from time 0 to 24 h; AUMC0–24h,area
under the first moment curve from time 0 to 24 h; MRT0–24h, mean residence
time from time 0 to 24 h; AUC0–72h,area under the concentration-time curve
from time 0 to 72 h; AUC0–∞,area under the concentration-time curve from time
0 to infinity; AUMC0–∞,area under the first moment curve from time 0 to in-
finity; MRT0–∞, mean residence time from time 0 to infinity; V/F, apparent
volume of distribution during terminal phase; CL/F, apparent total clearance of
the drug from plasma; V2/F, volume of distribution for central compartment;
CL2/F, clearance between compartments.
The bracketed values were calculated manually by the logarithmic trapezoidal
method as this method is recommended for post-peak plasma data
(Chiou, 1978). SE not provided as observations from a subset of animals (n = 1
– 3) at each timepoint (timepoint variability provided in Fig. 1 and Table 2)
were used to construct the PK curve from which these indices were calculated.
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administration. Parenteral delivery, however, is not viable in small
species as enrofloxacin causes pain, local tissue swelling and necrosis at
the injection site (Prezant et al., 1994; Young et al., 1997; Perry and
Mitchell, 2019). Variability may have also been introduced because it
was necessary to use a sampling method where an individual animal
represented each sampling timepoint. However, similar methods have
been used successfully in other studies when the study animal was small
or rare, there was a need to minimise stress and discomfort or blood
volumes (Sanchez-Migallon Guzman et al., 2010; Innis et al., 2012;
Musser et al., 2013; Kinney et al., 2014; Cerreta et al., 2019).
5. Conclusion
This study shows that single oral administration of enrofloxacin at
10 mg/kg in Asian house geckos achieves plasma concentrations that,
assuming mammalian susceptibility breakpoints may be effective at
treating E. lacertideformus and comparable bacterial pathogens with
fluoroquinolone MICs ≤ 0.5 µg/mL. Given that similar pharmacoki-
netic parameters would be expected in other small reptiles, including
the critically endangered reptiles threatened by E. lacertideformus on
Christmas Island, these findings provide baseline data that can be used
as a basis for the treatment of other small lizard species. However, the
impact of PPB and other factors on reptile tissue concentrations of en-
rofloxacin are not known. Additionally, as E. lacertideformus forms a
biofilm, and an immune response was absent from infected hosts, the
only means to ultimately determine the true efficacy of enrofloxacin
would be to conduct an experimental therapeutic trial in infected li-
zards.
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